NiKang Therapeutics’ $50 Million Series B Financing


Wilson Sonsini Goodrich & Rosati advised NiKang Therapeutics on the deal.

NiKang Therapeutics, an early stage biotech company focused on developing novel small molecule oncology drug discovery, announced the completion of a Series B financing for $50 million. The financing was led by RTW Investments, LP, with additional support from existing investor CBC Group, and from new investors including Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, and Octagon Capital.

NiKang will use the proceeds to support the preclinical and clinical development of several promising oncology programs and further enhance the company’s drug discovery pipeline.

The Wilson Sonsini team advising NiKang Therapeutics includes partner Dan Koeppen (Picture), associate Kassandra Castillo, and venture counsel Tim Conroy.

Involved fees earner: Kassandra Castillo – Wilson Sonsini Goodrich & Rosati; Tim Conroy – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: NiKang Therapeutics;

Author: Ambrogio Visconti